Tower Research Capital (TRC)’s Fennec Pharmaceuticals FENC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $26.7K | Buy |
4,339
+2,955
| +214% | +$22.8K | ﹤0.01% | 3273 |
|
|
2025
Q4 | $10.7K | Sell |
1,384
-240
| -15% | -$1.97K | ﹤0.01% | 3725 |
|
|
2025
Q3 | $15.2K | Sell |
1,624
-4,836
| -75% | -$41.9K | ﹤0.01% | 3553 |
|
|
2025
Q2 | $53.6K | Buy |
6,460
+4,765
| +281% | +$32.6K | ﹤0.01% | 2916 |
|
|
2025
Q1 | $10.3K | Sell |
1,695
-501
| -23% | -$3.22K | ﹤0.01% | 3652 |
|
|
2024
Q4 | $13.9K | Sell |
2,196
-253
| -10% | -$1.3K | ﹤0.01% | 3499 |
|
|
2024
Q3 | $12.2K | Sell |
2,449
-2,098
| -46% | -$12.1K | ﹤0.01% | 3607 |
|
|
2024
Q2 | $27.8K | Buy |
4,547
+4,157
| +1,066% | +$34.5K | ﹤0.01% | 3547 |
|
|
2024
Q1 | $4.34K | Sell |
390
-2,658
| -87% | -$26.7K | ﹤0.01% | 4692 |
|
|
2023
Q4 | $34.2K | Buy |
3,048
+1,578
| +107% | +$13.1K | ﹤0.01% | 3351 |
|
|
2023
Q3 | $11K | Buy |
1,470
+844
| +135% | +$6.87K | ﹤0.01% | 4042 |
|
|
2023
Q2 | $5.53K | Sell |
626
-2,492
| -80% | -$20.7K | ﹤0.01% | 4821 |
|
|
2023
Q1 | $26K | Buy |
3,118
+26
| +0.8% | +$241 | ﹤0.01% | 3150 |
|
|
2022
Q4 | $29K | Sell |
3,092
-519
| -14% | -$4.59K | ﹤0.01% | 2772 |
|
|
2022
Q3 | $29K | Sell |
3,611
-366
| -9% | -$2.51K | ﹤0.01% | 3620 |
|
|
2022
Q2 | $23K | Buy |
3,977
+3,839
| +2,782% | +$22.3K | ﹤0.01% | 3642 |
|
|
2022
Q1 | $1K | Sell |
138
-5,832
| -98% | -$29.4K | ﹤0.01% | 5779 |
|
|
2021
Q4 | $26K | Buy |
+5,970
| New | +$44.4K | ﹤0.01% | 3382 |
|
|
2021
Q2 | – | Sell |
-5,075
| Closed | -$31K | – | 5571 |
|
|
2021
Q1 | $31K | Buy |
5,075
+205
| +4% | +$1.54K | ﹤0.01% | 3537 |
|
|
2020
Q4 | $36K | Sell |
4,870
-15,937
| -77% | -$121K | ﹤0.01% | 3421 |
|
|
2020
Q3 | $126K | Buy |
20,807
+19,631
| +1,669% | +$138K | ﹤0.01% | 2953 |
|
|
2020
Q2 | $10K | Buy |
+1,176
| New | +$8.75K | ﹤0.01% | 4005 |
|
|
2020
Q1 | – | Sell |
-1,163
| Closed | -$7K | – | 3290 |
|
|
2019
Q4 | $7K | Buy |
1,163
+753
| +184% | +$4.04K | ﹤0.01% | 2508 |
|
|
2019
Q3 | $2K | Buy |
+410
| New | +$1.81K | ﹤0.01% | 3679 |
|
|
2019
Q2 | – | Sell |
-3,512
| Closed | -$17K | – | 3869 |
|
|
2019
Q1 | $17K | Buy |
+3,512
| New | +$23.1K | ﹤0.01% | 2358 |
|
|
2018
Q4 | – | Sell |
-311
| Closed | -$3K | – | 3963 |
|
|
2018
Q3 | $3K | Buy |
+311
| New | +$2.88K | ﹤0.01% | 3300 |
|
|
2018
Q2 | – | Sell |
-82
| Closed | -$1K | – | 3766 |
|
|
2018
Q1 | $1K | Sell |
82
-1,009
| -92% | -$9.53K | ﹤0.01% | 3063 |
|
|
2017
Q4 | $14K | Buy |
1,091
+691
| +173% | +$6.89K | ﹤0.01% | 2314 |
|
|
2017
Q3 | $4K | Buy |
+400
| New | +$4.64K | ﹤0.01% | 3389 |
|
Other funds holding FENC
RA
SCA
SCM
ACM
VCM
AIC
PCM
Tower Research Capital (TRC)'s FENC Position: Q1 2026 in Review
Tower Research Capital (TRC) increased its Fennec Pharmaceuticals (FENC) stake by 214% in Q1 2026, buying an estimated $22.8K and bringing the position to 4,339 shares worth $26.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3273.
Tower Research Capital (TRC) first reported a position in FENC in Q3 2017 and has held it in 29 quarters since. The position peaked at $126K in Q3 2020. 90 funds tracked by Wall St. Rank hold FENC as of Q1 2026.
- Tower Research Capital (TRC) held 4,339 shares of Fennec Pharmaceuticals worth $26.7K as of Q1 2026.
- Tower Research Capital (TRC) bought 2,955 Fennec Pharmaceuticals shares in Q1 2026, an estimated $22.8K.
- Fennec Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3273 holding.
- Tower Research Capital (TRC) first reported a position in Fennec Pharmaceuticals in Q3 2017 and has held it in 29 quarters since.
- Tower Research Capital (TRC)'s Fennec Pharmaceuticals position peaked at $126K in Q3 2020.
- 90 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.